Fresh Tracks Therapeutics, Inc. Common Stock
FRTX
FRTX was delisted on the 18th of December, 2023.
16 hedge funds and large institutions have $224K invested in Fresh Tracks Therapeutics, Inc. Common Stock in 2022 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, 5 reducing their positions, and 3 closing their positions.
6% less funds holding
Funds holding: 17 → 16 (-1)
32% less capital invested
Capital invested by funds: $328K → $224K (-$104K)
33% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 3
40% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
+$17.7K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
+$5.17K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$613 |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$11 |
| 5 |
Wells Fargo
San Francisco,
California
|
+$2 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BTI
Blue Trust Inc
Alpharetta,
Georgia
|
-$71.2K |
| 2 |
PCM
Palisade Capital Management
Fort Lee,
New Jersey
|
-$40K |
| 3 |
TSS
Two Sigma Securities
New York
|
-$19K |
| 4 |
Millennium Management
New York
|
-$13.3K |
| 5 |
TI
Telemetry Investments
New York
|
-$1.77K |
FRTX Hedge Fund Activity: Q4 2022 in Review
16 of the 6,222 institutional investors tracked by Wall St. Rank reported a position in Fresh Tracks Therapeutics, Inc. Common Stock (FRTX) for Q4 2022, worth a combined $224K — down 32% from $328K a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of FRTX and 2 opened new positions — a net loss of 1 holder — while 5 trimmed existing stakes and 3 added.
The largest buyer was Silverarc Capital Management, opening a new position worth an estimated $17.7K. The largest seller was Blue Trust Inc, cutting an estimated $71.2K.
- 16 institutional investors held Fresh Tracks Therapeutics, Inc. Common Stock (FRTX) as of Q4 2022, down from 17 in Q3 2022.
- Funds reported $224K of Fresh Tracks Therapeutics, Inc. Common Stock stock for Q4 2022, down 32% quarter-over-quarter.
- 2 funds opened new Fresh Tracks Therapeutics, Inc. Common Stock positions in Q4 2022 and 3 closed out, a net change of -1 holder.
- The largest Fresh Tracks Therapeutics, Inc. Common Stock buyer in Q4 2022 was Silverarc Capital Management, an estimated $17.7K added.
- The largest Fresh Tracks Therapeutics, Inc. Common Stock seller in Q4 2022 was Blue Trust Inc, an estimated $71.2K sold.
Based on aggregated 13F filings for Q4 2022.